New blog about Mylan recalls EpiPen auto-injectors due to failure to activate
Attention, allergy parents: Your child’s epinephrine injection could be part of a voluntary recall affecting EpiPen and EpiPen Jr auto-injectors.
Meridian Medical Technologies, Mylan’s manufacturing partner for EpiPen auto-injector, has announced a recall of 13 lots of the medication due to a potential failure to activate the device in an emergency. The possible defect could cause the life-saving device to require increased force in order to activate, or to fail altogether — resulting in significant danger for a patient having an allergic reaction.
This recall comes as a result of two reports outside of the U.S. of failure to activate due to a potential defect in a supplier component. Although the incidence of the defect is extremely rare, the recall has been issued for extra caution.
Is your EpiPen affected?
• The recall impacts the 0.3 mg and 0.15 mg strengths of EpiPen Auto-Injector.
• None of the 13 recalled lots include the authorized generic for EpiPen Auto-Injector.
• Lots included in this recall were manufactured by Meridian Medical Technologies and distributed by Mylan Specialty between December 2015 and July 2016.
• Click here for a complete list of affected medication in the U.S.
What you should do
If you think you’ve been affected by this recall, here’s what you need to do:
1) Check the lot number on your carton or device.
2) If your EpiPen auto-injector has been recalled, contact Stericycle at 877-650-3494 to obtain a voucher code for your free replacement product. (Hours of operation are 8 a.m. to 10 p.m. (ET) Monday to Friday and 8 a.m. to 5 p.m. Saturday and Sunday.) Stericycle will provide a pre-paid return package to ship the product back to Stericycle.
3) Visit your pharmacy with your voucher information to redeem your free replacement.
4) Send your recalled product to Stericycle. Do not return any devices affected by the recall until you have your replacement in hand.

Images by Mylan
Dont forget to visit our Baby Shop

Comments
Post a Comment